Latest Edison Report Values KZA at $1.91 per share, page-30

As we all know many many commercial drugs are not a cure they are beneficial In that they either ease conditions to a reasonable level of comfort or prolong life by some meaningful amount... many conditions are something you live with within a maintenance program.

Its great that Paxalislib / GDC0084 is also gaining more attention for uses outside oncology!

This is a very interesting and potentially explosive value driving path of research for us and this incredible compound... I’m amazed we continue to find new discussions and new paths of application. It seems another interesting avenue presents itself each quarter.

With GBM AGILE moving us closer to FDA approval in the fastest most cost effective way - we may find ourselves with an approved drug and multiple markets too boot.